Shape Therapeutics Inc. developed Programmable ADAR-based RNA editing for engineering immunogenic editopes as directed cancer immunotherapy.
Published
Signal category
Research & Knowledge
Quote
“Programmable ADAR-based RNA editing for engineering immunogenic editopes as directed cancer immunotherapy”
— Yiannis Savva, PhD|Shape Therapeutics Inc. team
Company
Shape Therapeutics Inc.
The future of programmable RNA Medicines
- Industry
- Biotechnology Research
- Location
- Seattle, US
- Company size
- 32 employees
ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and disruptive gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more.
Founded 2018